Private Label Tranexamic Acid Sunscreen Manufacturer Low MOQ

Most manufacturers who can legally produce an SPF product in the United States set a minimum order quantity between 500 and 2,000 finished units for a private label tranexamic acid sunscreen. The wide range exists because SPF products are regulated as OTC drugs by the FDA, not as conventional cosmetics, and the compliance overhead — cGMP manufacturing, batch records, SPF efficacy testing — makes very small runs economically difficult for most facilities. At 500 units, you are at the low end of what OTC-capable manufacturers will typically accept, and you should expect a higher per-unit cost to compensate for setup time and the fixed cost of SPF testing, which runs roughly $2,500–$5,000 regardless of batch size. Some Korean contract manufacturers — particularly those with KFDA OTC equivalency and established relationships with US importers — can go as low as 300 units for a hybrid mineral-chemical formula, but importation, FDA registration, and labeling compliance add complexity that first-time founders often underestimate. For a custom formula (meaning you want your own specific TXA percentage, UV filter blend, and texture profile rather than a stock base with your label), MOQ floors tend to rise to 1,000–2,000 units because the formulation and stability testing investment must be spread across a meaningful production run to make the project viable for the manufacturer. Several things can move the MOQ lower: choosing a stock or semi-custom base that the manufacturer already has SPF data on (since testing is already complete), committing to a simple packaging component from the manufacturer's existing inventory, or agreeing to a slightly longer lead time that lets them batch your order with another client's run. If MOQ is your primary constraint, always open the negotiation by asking what stock-formula options they have with SPF efficacy data already in hand — that single question can cut your MOQ requirement in half. Platforms like AJ Cosmo Labs let you filter manufacturers specifically by MOQ range and OTC drug capability, which saves weeks of cold outreach to suppliers who ultimately can't meet your project requirements.

The realistic end-to-end timeline for a private label tranexamic acid sunscreen — from initial manufacturer contact to product in your hands ready to sell — is 16 to 28 weeks. That wide window is driven almost entirely by the regulatory testing requirements for SPF products and whether you are adapting a stock formula or building a custom one. Weeks 1–3 cover initial scoping: NDA signing, project brief submission, manufacturer review, and formula selection or custom development brief. If you are selecting a stock base that already has SPF efficacy data on file, you can cut this phase down to 1–2 weeks because the manufacturer is not starting formula development from scratch. Weeks 3–8 cover formula development and bench-top sampling for custom projects. A cosmetic chemist will prototype your TXA concentration, UV filter blend, and skin-feel profile, then produce a lab-scale sample for your evaluation. Expect 1–3 rounds of sample revision. If you are going with a pre-developed stock base, skip to week 8. Weeks 8–18 cover SPF and broad-spectrum testing. This is the single biggest timeline driver and cannot be compressed. FDA OTC monograph compliance requires SPF efficacy testing (in-vivo or in-vitro per current guidance), broad-spectrum testing, and water-resistance testing if you make that claim. Accredited labs like Eurofins or AMA Laboratories typically quote 8–12 weeks for a full SPF test battery. Stability testing (accelerated at 40°C/75% RH for 12 weeks) can run in parallel during this window rather than sequentially. Weeks 14–22 cover packaging procurement and label artwork finalization. OTC drug labels must comply with the FDA OTC labeling monograph (Drug Facts panel, active ingredient declaration, required warnings). Your manufacturer or a regulatory consultant should review the label before print. Packaging components — especially custom bottles or airless pumps — can have 8–14 week lead times themselves if you are not pulling from manufacturer stock. Weeks 20–28 cover production filling, batch release testing, and shipment. A batch of 1,000–2,000 units typically fills in 1–3 days, but QC and batch release documentation add 1–2 weeks before the manufacturer ships. The fastest possible timeline — stock formula, stock packaging, off-the-shelf labels, no custom development — is approximately 10–14 weeks, because SPF testing is the irreducible bottleneck. Budget for the longer end if this is your first OTC product. AJ Cosmo Labs lets you post your timeline requirements upfront in your project brief so manufacturers who cannot meet your window simply don't apply, saving you from discovering a conflict six weeks into the process.

The United States does not have a pre-market approval process for most OTC sunscreens sold under the existing FDA monograph system, but that does not mean you can sell freely without compliance steps. Sunscreens are regulated as OTC drug products under 21 CFR Part 352 (and more recently under the ongoing Sunscreen Innovation Act and proposed OTC monograph modernization rules). This means there are specific, mandatory requirements your product must meet before it can legally be sold in the US. First, your manufacturer must be registered with the FDA as a Drug Establishment. This is a non-negotiable requirement. Manufacturing at a facility that lacks this registration makes your product misbranded and adulterated under federal law, regardless of how safe or effective it is. Second, the active UV filter ingredients you use must appear on the FDA's approved OTC sunscreen monograph ingredient list. As of 2024, only 16 UV filters have been proposed for generally-recognized-as-safe-and-effective (GRASE) status, and the FDA has identified two (zinc oxide, titanium dioxide) as GRASE Category I. If you want to use avobenzone, octinoxate, or certain other chemical filters, they remain in a category requiring additional safety data — but they are still in widespread commercial use while the regulatory process continues. Do not use oxybenzone or octinoxate if you plan to sell in Hawaii, which has banned them. Third, your product must carry a compliant Drug Facts panel. The format is strictly defined: active ingredients (with their permitted concentration ranges and UV filter designation), purpose, uses, warnings, directions, and inactive ingredients. Any deviation is a labeling violation. Fourth, SPF efficacy testing using an FDA-recognized method is required to substantiate any SPF number on your label. You cannot simply declare SPF 30 — a certified testing lab must generate that data from your specific formula. Transexamic acid itself is not an FDA-approved drug active for OTC use, so it is treated as a cosmetic ingredient (inactive ingredient) within the Drug Facts panel framework. It must appear in the inactive ingredient list, not the active. This is an important distinction: your product is a drug because of the UV filters, not because of the TXA. For EU sales, sunscreens are cosmetics under Regulation 1223/2009 and require a Cosmetic Product Safety Report (CPSR) and notification on the CPNP portal before market entry. The EU's permitted UV filter list differs from the US list — several US-approved chemical filters are not permitted in the EU — so plan separate formulas if you intend to sell in both markets. AJ Cosmo Labs vets listed manufacturers for regulatory credentials including FDA Drug Establishment Registration, so you can filter out non-compliant facilities before you invest time in conversations.

Tranexamic acid is used in leave-on cosmetic formulations at concentrations typically ranging from 2% to 5% by weight. Within sunscreen formulations specifically, the most commercially common range is 2%–3%, with some premium or clinical-positioning products using up to 5%. The reason concentrations don't go much higher in a sunscreen context is multifactorial. TXA is a water-soluble amino acid derivative, and at concentrations above 5% in an emulsion system, you begin to encounter texture and skin-feel issues — grittiness, tackiness, or reduced spreadability — that conflict with consumer expectations for a daily SPF product, which is already competing against the white-cast and heaviness associated with high-UV-filter loads. Stability is the second constraint. Tranexamic acid is relatively stable at pH 5.0–6.5, which is compatible with most cosmetic emulsion systems. However, chemical UV filters like avobenzone are notoriously photolabile and are typically stabilized with photostabilizers (e.g., Tinosorb S, Bemotrizinol, or octocrylene — though octocrylene carries its own consumer perception challenges). The cosmetic chemist formulating your product needs to confirm that your TXA concentration doesn't interact with the stabilizer system or shift the formula pH into a range where UV filter degradation accelerates. Mineral-only formulas (zinc oxide, titanium dioxide) are generally more compatible with TXA because the pH window is more forgiving and there is no photolabile filter chemistry to protect. Many low-MOQ manufacturers building stock TXA sunscreen bases default to a hybrid or mineral-only approach for exactly this reason — it simplifies stability. From a consumer efficacy standpoint, published clinical literature on TXA for hyperpigmentation most commonly references topical concentrations of 2%–5% used twice daily over 8–12 weeks. If your brand positioning includes skin-brightening claims supported by clinical data, you should target the mid-to-upper end of that range (3%–5%) and ensure your claims language is carefully reviewed by a regulatory consultant — brightening claims can edge into drug territory if they reference melanin inhibition mechanisms. Always request stability data from your manufacturer at your target TXA percentage in the specific formula base you are using. Bench-top data at 40°C/75% RH over 12 weeks (accelerated stability) is the minimum acceptable evidence before you commit to a production run. Real-time 12-month stability should follow for regulatory and quality assurance purposes.

Finding a low-MOQ private label sunscreen manufacturer who is also OTC drug compliant is genuinely difficult using general sourcing directories, because most databases don't filter for FDA Drug Establishment Registration, SPF testing capability, or TXA formulation experience simultaneously. Here is a practical sourcing framework. Step one is defining your non-negotiable requirements before you contact anyone: target SPF, filter preference (mineral, chemical, hybrid), TXA percentage, unit size, packaging format, MOQ ceiling, and timeline. Having these in a one-page brief — not a vague inquiry — signals to manufacturers that you are a serious buyer and dramatically improves response quality. Step two is verifying FDA registration. Go to the FDA's Drug Establishment Registration and Drug Listing database (accessible at fda.gov) and confirm any prospective manufacturer's registration number. This takes under five minutes and immediately eliminates non-compliant facilities. Do not skip this step even if a manufacturer claims compliance verbally. Step three is asking for SPF experience specifically: how many SPF SKUs have they manufactured in the past 12 months, what testing labs do they work with, and can they provide a certificate of analysis from a previous SPF batch? A manufacturer with genuine SPF experience will answer these questions without hesitation. Step four is asking about TXA specifically: have they formulated with it before, at what concentration, and in what vehicle (serum, cream, fluid)? Can they share a stability summary (not full proprietary data, but a summary showing the formula was stable at 40°C/75% RH)? This filters out manufacturers who would be learning on your dime. Step five is requesting an itemized quote — not a per-unit number — so you can see raw material cost, fill cost, testing cost, and overhead separately. This lets you identify which line items are negotiable and where the manufacturer's margin actually sits. Step six is using purpose-built sourcing platforms rather than generic manufacturer directories. AJ Cosmo Labs is an iOS app designed specifically for CPG founders sourcing cosmetic and OTC product manufacturers. You post a brief, and vetted manufacturers with the relevant capabilities respond — rather than you cold-emailing a list of facilities hoping one qualifies. The platform admin-reviews manufacturers, with certifications on file, and allows you to filter by MOQ, product type, and region. Download the AJ Cosmo Labs app from the App Store to post your TXA sunscreen brief and start receiving responses from qualified SPF manufacturers within days, not weeks.

Yes, tranexamic acid and SPF actives can be combined in a single finished product, and the market has validated this combination commercially — several K-beauty and clinical skincare brands have launched stable, well-reviewed TXA + SPF formulas. However, the combination presents formulation challenges that require an experienced cosmetic chemist to navigate, and a poorly executed formula will fail stability testing or underperform on consumer experience. The primary technical tension is between the water-soluble, polar nature of tranexamic acid and the emulsification demands of a high-SPF formula. UV filters, especially chemical ones, tend to be oil-soluble and require specific emulsifier systems and rheology modifiers to remain stable and spread evenly. Adding a high concentration of a water-soluble active like TXA can disrupt the water phase osmotic balance of the emulsion, particularly if the formula is already at the edge of stability due to a high UV filter load. Mineral-only SPF formulas (zinc oxide, titanium dioxide) tend to be more forgiving in this regard because the UV-blocking mechanism is physical rather than chemical, and the pH window compatible with mineral filters overlaps well with TXA's stability range. If you're working with a low-MOQ manufacturer sourcing from a stock base, ask specifically about mineral or hybrid bases that already incorporate a brightening active — some manufacturers have done this formulation work already. Chemical filter systems, particularly those relying on avobenzone, require photostabilizers that introduce additional compatibility variables. Octocrylene is commonly used as an avobenzone stabilizer but has faced consumer and regulatory scrutiny (benzophenone contamination concerns); alternative stabilizers like Tinosorb M or S are effective but are not approved US OTC monograph ingredients, making them unavailable for US-market chemical-filter formulas. This is one reason many new TXA sunscreen launches default to mineral or hybrid systems. From a consumer efficacy standpoint, combining TXA and SPF in one product makes strong commercial sense: UV exposure is one of the primary triggers of post-inflammatory hyperpigmentation and melasma, so protecting the skin while simultaneously inhibiting tyrosinase activity creates a synergistic product story. The two functions genuinely support each other mechanistically. The common mistake founders make is assuming any SPF manufacturer can simply add TXA to an existing sunscreen formula. Without stability testing of the specific combined formula, you have no data showing the TXA remains active and the SPF rating holds through the product's shelf life. A reputable manufacturer will insist on at minimum accelerated stability testing (12 weeks at 40°C/75% RH) before commercialization. Budget for this — it's not optional, and a manufacturer who skips it is a red flag.

A tranexamic acid sunscreen sold in the United States must carry an OTC drug label formatted according to FDA regulations, because the sunscreen actives make it a drug product. The labeling requirements are detailed in 21 CFR Part 201 and the OTC sunscreen monograph, and non-compliance can result in the product being considered misbranded — which can trigger warning letters, import alerts, or market withdrawal. The Drug Facts panel is the centerpiece of OTC sunscreen labeling. It must appear on the outer packaging (and the immediate container if space allows) in a specific format with defined font sizes, header hierarchy, and section order: Active Ingredients, Purpose, Uses, Warnings, Directions, Other Information, and Inactive Ingredients. The FDA's OTC labeling guidance provides a template — do not deviate from the layout even for design reasons. Active ingredients must be listed with their exact INCI name and permitted concentration as defined in the monograph. For example, Zinc Oxide 19% or Avobenzone 3%. Tranexamic acid is NOT an approved OTC drug active and must appear in the Inactive Ingredients section, listed in descending order of concentration along with all other non-active components. The SPF number on the label must be substantiated by the testing data your manufacturer obtained from an accredited lab. You cannot list SPF 50 if your test result was SPF 47 — round down, not up. Broad-spectrum claims require a separate critical wavelength test showing λc ≥ 370 nm. Water-resistance claims (40-minute or 80-minute) require their own in-vivo or in-vitro test protocol. Product name and marketing language on the principal display panel must not imply drug uses beyond what the OTC monograph permits. Brightening language ("evens skin tone," "reduces dark spots") is generally acceptable as a cosmetic claim, but mechanistic language that implies the TXA is treating a disease ("treats melasma," "inhibits melanin overproduction") can cause the product to be classified as a new drug requiring full FDA approval — a critical distinction your regulatory counsel must review. For products sold online and shipped across US states, federal labeling requirements apply uniformly. California's Proposition 65 may require additional warnings depending on your UV filter selection — check whether any active or inactive ingredients appear on the current Prop 65 list. Hawaii's sunscreen restrictions (banning oxybenzone and octinoxate for environmental protection) apply to products sold or distributed in Hawaii, including online sales shipped to Hawaii addresses. AJ Cosmo Labs connects founders with manufacturers who have in-house regulatory affairs support or established relationships with OTC regulatory consultants, which can significantly reduce the risk of label errors that delay your launch.